New Cannabinoid Clinical Trials: CBD Titration in Adult LGS, Cancer Use Tracking, and Stress in Cannabis Use Disorder
| Audience | Patients, clinicians, healthcare professionals, regulators, and industry researchers. |
| Primary Topic | Three cannabinoid clinical trials: LGS, cancer care, and cannabis use disorder . |
| Source | Read the full source |
New Cannabinoid Clinical Trials: CBD Titration in Adult LGS, Cancer Use Tracking, and Stress in Cannabis Use Disorder
Three cannabinoid studies registered on ClinicalTrials.gov are worth watching: an open-label trial of gradual prescription CBD titration in 40 adults with Lennox-Gastaut syndrome, an app-based cannabis journal study in cancer care, and a stress-hormone study in cannabis use disorder. None has posted results yet, so patients should not change treatment based on these registrations.
A physician-led look at three cannabinoid studies on ClinicalTrials.gov: a CBD titration trial in adults with Lennox-Gastaut syndrome, an app-based cannabis journal study in cancer care, and a laboratory study of stress hormones and cannabis craving.
| Feature | EpiGOAL (NCT07728097) | COSMIC-Releaf (NCT07089225) | COBRAS (NCT06430580) |
|---|---|---|---|
| Design | Open-label interventional, Phase 3b/4 | Observational pilot cohort | Randomized, placebo-controlled, double-blind crossover, Early Phase 1 |
| Enrollment | 40 planned | 45 planned | 38 enrolled |
| Population | Adults with Lennox-Gastaut syndrome taking 1 to 3 antiseizure medications | Adults with cancer who obtain cannabis from licensed stores | Adults 18 to 50 with moderate-to-severe cannabis use disorder |
| Primary outcome | 50% or greater reduction in major motor seizures at week 24 | Pattern of cannabis use over 6 months | EEG response to cannabis cues and cannabis demand measures |
| Status | Not yet recruiting (planned start Nov. 18, 2026) | Recruiting | Completed (Aug. 2026) |
| Results posted | No | No | No |
| Sponsor | Jazz Pharmaceuticals | Scot Remick, MD (MaineHealth Cancer Care), with the National Cancer Institute | Florida State University, with the National Institute on Drug Abuse |
Source: ClinicalTrials.gov records accessed October 22, 2026.
| Post Type | Cannabis News & Regulatory Digest using canonical CED layout |
| Items Reviewed | 3 verified updates |
| Primary Dates | October 22, 2026 |
| Related Reading | 3 verified live CED Clinic internal links |
| Update 1 | A Study in Patients Reporting (Scot Remick Trial Registration) |
| Update 2 | A Study to Investigate the (Jazz Pharmaceuticals Trial Registration) |
| Update 3 | Cannabinoids and Biological Reactivity to (Florida State University Trial Registration) |
This curated cannabis news & regulatory digest brings together 3 key developments in cannabinoid clinical research. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.
Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.
Title & Source: Clinical Trial: A Study in Patients Reporting Cannabis Use Followed With an Application-Based Cannabis Journal (Scot Remick, 2026-10-22)
Lead Authors & Identifiers: Scot Remick. Content lane: Protocol Watch.
Study Design: This observational study uses a mobile application to collect real-world data from cancer patients who use cannabis. The researchers aim to fill a significant gap in clinical knowledge regarding how this population uses cannabinoids for symptom management.
What It Measures: The study focuses on the feasibility of app-based reporting and the diversity of cannabis products used by oncology patients. Its primary outcome is the pattern of cannabis use over six months, including frequency, dose, product type, route, and THC and CBD content, with patient-reported helpful and adverse effects as secondary outcomes. The pilot plans to enroll 45 patients at MaineHealth Cancer Care, with National Cancer Institute collaboration.
Clinical Relevance: Encourage patients to use digital tools to record their usage patterns and symptom changes. This data is invaluable for identifying which products provide the most relief with the fewest side effects.
Practical Boundaries: The study relies on self-reported data, which can be inconsistent or influenced by patient expectations.
Title & Source: Clinical Trial: A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS (Jazz Pharmaceuticals, 2026-10-22)
Lead Authors & Identifiers: Jazz Pharmaceuticals. Content lane: Protocol Watch.
Study Design: This open-label Phase 3b/4 trial (EpiGOAL), planned for 40 adults and not yet recruiting as of October 2026, investigates the optimization of CBD-OS as an add-on therapy for adults with Lennox-Gastaut Syndrome. The study specifically evaluates the impact of a gradual titration schedule on patient outcomes and safety.
What It Measures: Its primary outcome is the share of participants with at least a 50% reduction in major motor seizures by week 24. Secondary outcomes track treatment retention, seizure-free days, caregiver-rated severity, laboratory abnormalities, and adverse events leading to discontinuation.
Clinical Relevance: Follow a strict, slow titration schedule when introducing high-dose CBD to minimize the risk of gastrointestinal or hepatic issues. Gradual increases allow for better assessment of the minimum effective dose.
Practical Boundaries: The findings are specific to a pharmaceutical CBD formulation and may not apply to over-the-counter products.
Title & Source: Clinical Trial: Cannabinoids and Biological Reactivity to Stress (Florida State University, 2026-10-22)
Lead Authors & Identifiers: Florida State University. Content lane: Clinical Evidence Update.
Study Design: This Early Phase 1 study examines the relationship between pharmacological stress induction and the motivation to use cannabis. In a randomized, placebo-controlled, double-blind crossover design, 38 adults with moderate-to-severe cannabis use disorder received hydrocortisone, yohimbine, both, or placebo across four lab visits.
What It Measures: Researchers measured brain responses to cannabis images by EEG and cannabis demand on a purchase task, with blood endocannabinoid levels as an exploratory outcome. The study was completed in August 2026, but results had not been posted to ClinicalTrials.gov as of October 22, 2026, so no conclusions about stress and craving can be drawn yet.
Clinical Relevance: Help patients identify their specific stress triggers to develop alternative coping strategies. Understanding the biological drive behind the urge to use can reduce patient guilt and improve treatment adherence.
Practical Boundaries: The small sample size and laboratory setting may not reflect the complexity of real-world stress.
The current clinical environment is shifting from general observation to granular data collection. By integrating digital health tools like mobile journals into oncology care, researchers are finally capturing the nuances of how patients use various chemotypes and delivery methods. This move toward real-world evidence complements the rigorous, phase-controlled trials conducted by pharmaceutical companies.
Simultaneously, the focus on titration protocols reflects a maturing understanding of cannabinoid pharmacokinetics. We are moving past the era of ‘start low and go slow’ as a vague suggestion and toward specific, data-driven schedules that aim to reach therapeutic windows more efficiently. This precision is vital for patients with severe conditions like LGS where the margin for error is narrow.
I see many patients who feel lost in the trial-and-error phase of cannabis use. They often arrive with a bag of products but no clear record of what worked or why it failed. The introduction of app-based journaling in a clinical trial setting validates what I have encouraged for years: the patient is the most important data source. When we formalize this process, we turn anecdotal experience into a clinical tool that can inform future treatment plans.
The emphasis on titration in the LGS study is particularly relevant. In my experience, many side effects that lead patients to discontinue therapy are actually the result of rushing the dose. A structured, gradual approach allows the endocannabinoid system to adapt, which often preserves the therapeutic benefit while keeping the patient comfortable. This is a lesson that applies far beyond epilepsy.
Finally, the research into stress and use motivation reminds us that cannabis use is often a functional behavior. Patients are frequently trying to solve a physiological problem, such as a heightened stress response. By identifying these triggers, we can better support patients in finding the right balance between therapeutic use and dependency.
How to Interpret This Cannabis News & Regulatory Digest
These studies represent the evolution of cannabinoid medicine from anecdotal reports to structured clinical protocols and behavioral analysis.
Three Rules for Critical Reading
Distinguish Between Observational and Interventional Data
The oncology study tracks what patients are already doing, while the LGS study tests a specific, controlled intervention.
Look for Specific Titration Schedules
Effective cannabinoid therapy relies on the rate of dose escalation, which directly impacts both safety and efficacy.
Consider the Source of Stress
Behavioral studies using pharmacological triggers provide insight into the biology of use but may differ from psychological stress.
CED Perspective Lens: Eight Viewpoints on These Updates
Why these developments matter across clinical, patient, safety, and policy perspectives
Empowering Your Treatment with Data
You might find it helpful to know that researchers are finally looking at how you use cannabis in your daily life. By using apps to track your symptoms and doses, you contribute to a larger body of knowledge that helps other patients.
This shift toward better tracking means your doctor can give you more specific advice. Instead of guessing, you can use your own data to find the products that work best for your needs. In clinical practice, evaluating patient factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Standardizing Cannabinoid Protocols
These studies highlight the importance of moving toward structured titration and formal data collection in your practice. The LGS trial provides a model for how we can manage complex patients by prioritizing a slow, methodical approach to dosing.
Integrating digital tracking tools can help you bridge the communication gap with patients who use cannabis. This objective data allows for more precise adjustments to their treatment plans and better safety monitoring. In clinical practice, evaluating clinician factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Minimizing Risks Through Gradual Dosing
Safety in cannabinoid medicine is closely tied to the rate of dose escalation and the consistency of the product. The focus on gradual titration in recent trials is a positive step toward reducing avoidable adverse reactions.
Monitoring for stress-induced use patterns can also help identify patients at risk for developing dependency. By addressing the underlying triggers, we can promote a more sustainable and safer relationship with the medicine. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
The Role of Real-World Evidence
Regulatory bodies are increasingly looking for real-world evidence to inform policy decisions regarding cannabis. Studies that use mobile journals to capture patient data provide the kind of large-scale information that regulators need.
Standardizing titration and dosing protocols through clinical trials also helps establish a framework for product labeling and medical guidelines. This move toward pharmaceutical-grade rigor is essential for the long-term integration of cannabis into healthcare. In clinical practice, evaluating policy factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Advancing Digital Health in Cannabis
The use of digital health platforms in oncology research represents a significant advancement in how we study cannabis. This approach allows for the collection of high-volume data without the constraints of traditional clinical settings.
Investigating the biological mechanisms of stress and use motivation provides a foundation for developing targeted therapies for Cannabis Use Disorder. These early-phase studies are necessary for identifying the pathways that drive patient behavior. In clinical practice, evaluating research factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Evaluating Data Quality and Bias
It is important to remain cautious about self-reported data, as patients may not record their use accurately in their journals. We must also consider how manufacturer-sponsored trials might influence the presentation of titration benefits.
While laboratory stress tests are useful, they may not capture the full experience of a patient’s life. We need to see if these findings hold up in broader, more diverse populations over longer periods. In clinical practice, evaluating skeptic factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Supporting Patient Stability
For those caring for patients with complex conditions like LGS, the emphasis on slow titration is a helpful guide. It suggests that patience in the dosing process is key to finding the right balance for your loved one.
Helping the patient maintain a simple log of their symptoms and doses can make a big difference in their care. This information helps the medical team make better decisions and ensures the patient stays comfortable. In clinical practice, evaluating caregiver factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
The Future of Precision Medicine
The common thread across these updates is the move toward precision and better data. Whether it is through app-based journals or formal titration trials, the goal is to make cannabis therapy more predictable.
By focusing on the details of how and why patients use cannabis, we can move away from generalities and toward personalized medicine. This approach benefits everyone from the patient to the researcher. In clinical practice, evaluating takeaway factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is the EpiGOAL trial of cannabidiol in adults with Lennox-Gastaut syndrome?
EpiGOAL (NCT07728097) is an open-label Phase 3b/4 study sponsored by Jazz Pharmaceuticals that plans to enroll 40 adults with Lennox-Gastaut syndrome already taking one to three antiseizure medications. It tests a gradual titration schedule for prescription cannabidiol oral solution, and its primary outcome is a 50% or greater reduction in major motor seizures by week 24.
Why does the titration schedule for prescription CBD matter?
Prescription cannabidiol commonly causes sleepiness, reduced appetite, and diarrhea, and its FDA labeling notes that liver enzyme elevations are more frequent when it is combined with valproate. A slower schedule may improve tolerability and help patients stay on treatment, which is why EpiGOAL tracks retention and adverse events alongside seizure counts.
What did the Florida State University stress and cannabis study test?
The COBRAS study (NCT06430580) gave 38 adults with moderate-to-severe cannabis use disorder hydrocortisone, yohimbine, both, or placebo in a double-blind crossover design, then measured EEG responses to cannabis cues and cannabis demand. It finished in August 2026, but results had not been posted as of October 22, 2026.
Why would a cancer study ask patients to log cannabis use in an app?
Many people with cancer use cannabis without structured follow-up. The COSMIC-Releaf pilot (NCT07089225) plans to follow 45 patients at MaineHealth Cancer Care for six months, recording product types, doses, routes, and THC and CBD content along with patient-reported helpful and adverse effects.
Do newly registered trials show that cannabinoids work?
No. A registry entry describes what researchers plan to measure, not what they found. None of these three studies had posted results as of October 22, 2026, and the LGS and cancer studies have no placebo comparison, so their eventual findings will need careful interpretation.
Cite This Article (AMA Style)
Caplan B. New Cannabinoid Clinical Trials: CBD Titration in Adult LGS, Cancer Use Tracking, and Stress in Cannabis Use Disorder. CED Clinic. Accessed October 22, 2026. https://cedclinic.com/new-cannabinoid-clinical-trials-lgs-cancer-cud/
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
